Additional cytogenetic features determine outcome in patients allografted for TP53 mutant acute myeloid leukemia.

MLA

Loke, Justin, et al. “Additional Cytogenetic Features Determine Outcome in Patients Allografted for TP53 Mutant Acute Myeloid Leukemia.” Cancer (0008543X), vol. 128, no. 15, Aug. 2022, pp. 2922–31. EBSCOhost, https://doi.org/10.1002/cncr.34268.

APA

Loke, J., Labopin, M., Craddock, C., Cornelissen, J. J., Labussière, W. H., Wagner, D. E. M., Van Gorkom, G., Schaap, N. P. M., Kröger, N. M., Veelken, J. H., Rovira, M., Menard, A. L., Bug, G., Bazarbachi, A., Giebel, S., Brissot, E., Nagler, A., Esteve, J., & Mohty, M. (2022). Additional cytogenetic features determine outcome in patients allografted for TP53 mutant acute myeloid leukemia. Cancer (0008543X), 128(15), 2922–2931. https://doi.org/10.1002/cncr.34268

Chicago

Loke, Justin, Myriam Labopin, Charles Craddock, Jan J. Cornelissen, Wallet, Hélène Labussière, Drouet, Eva Maria Wagner, Gwendolyn Van Gorkom, et al. 2022. “Additional Cytogenetic Features Determine Outcome in Patients Allografted for TP53 Mutant Acute Myeloid Leukemia.” Cancer (0008543X) 128 (15): 2922–31. doi:10.1002/cncr.34268.